GlassScriptPhysician profile
Matthew P Ostrom
NPI 1205033073
$61,040.85
in general payments reported to CMS, 2019-2025
47 companies · $12K in 2025
The $12K reported for 2025 was more than what 83% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,896 · 2020: $8,450 · 2021: $5,742 · 2022: $8,277 · 2023: $9,447 · 2024: $10K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,014 · Consulting Fee: $4,200 · Travel and Lodging: $2,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,000.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,013.75 |
| Consulting Fee | $4,200.00 |
| Travel and Lodging | $2,460.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18,616.17 | 2021-2025 | Micra, Epsila Ev, Na |
| Boston Scientific Corporation | $15,960.69 | 2019-2025 | General - Ep, Rhythmia Mapping System, General - Therapies |
| Abbott Laboratories | $9,071.01 | 2019-2025 | Aveir, Gallant, Ensite |
| Cvrx, INC. | $4,758.58 | 2024-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $3,371.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $2,844.46 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $724.50 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $637.08 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $628.51 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $582.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $545.99 | 2019-2024 | Xarelto |
| Cardiva Medical, INC. | $414.60 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Atricure, INC. | $384.96 | 2019-2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Amgen INC. | $258.74 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $226.21 | 2020-2023 | Optimizer |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ostrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.